

 Content archived on 2024-06-18



Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment

Fact Sheet

Project Information

IMPACTT

Grant agreement ID: 261095

Project closed

Start date

1 January 2011

End date

31 December 2016

Funded under

Specific Programme "Cooperation": Health

Total cost

€ 7 055 166,59

EU contribution

€ 5 376 180,00

Coordinated by

UPPSALA UNIVERSITET



Sweden

This project is featured in...



Objective

Cystic Fibrosis (CF) is a chronically debilitating and life threatening medical condition. Respiratory insufficiency and complications of chronic lung infection lead to long term reduction in quality of life and health and even to premature death. Chronic bacterial infections with *Pseudomonas aeruginosa* (PA), *Staphylococcus aureus* and *Haemophilus influenzae* are typical for CF and repeated courses of antibiotics in heavy doses has more than doubled the median survival age. No preventive or eradication treatments of PA infection in the lungs exist today. The most significant bacterial pathogen associated with CF pulmonary disease is PA. PA is an opportunistic, life-threatening gram-negative bacteria which produces various immune modulatory products enabling it to survive in the lungs and cause morbidity and mortality. CF patients are particularly at risk of infection due to the viscous mucus lining their airways, which compromises their respiratory function.

The European Medicines Agency granted “Anti-pseudomonas IgY” an Orphan Drug Designation in September 2008, and paediatric CF product development was encouraged. The IMPACTT project will perform a clinical phase III trial, to demonstrate the critical preventive and therapeutic effects of this pioneering intervention therapy for the fatal chronic infection of *Pseudomonas aeruginosa* in CF patients. The project mobilises the critical mass of experts from academia, patient organisations, clinical trials managers, clinicians and industry aiming to eradicate PA infection in CF patient lungs and thereby alleviate the negative impact of PA on the quality of life of CF patients and their families.

Despite good results with antibiotics, continuous pulmonary deterioration and death of the CF patient is a reality. Alternative therapeutic strategies are badly needed. Our phase I and II clinical studies prove that a single daily gargle with the proposed Anti-*Pseudomonas* IgY solution significantly improves the condition.

Fields of science (EuroSciVoc)

[social sciences](#) > [sociology](#) > [demography](#) > [mortality](#)

[natural sciences](#) > [biological sciences](#) > [microbiology](#) > [bacteriology](#)

[medical and health sciences](#) > [basic medicine](#) > [pharmacology and pharmacy](#) > [pharmaceutical drugs](#) > [antibiotics](#)



Programme(s)

Topic(s)

[HEALTH.2010.2.4.4-1 - Clinical development of substances with a clear potential as orphan drugs. FP7-HEALTH-2010-single-stage](#)

Call for proposal

FP7-HEALTH-2010-single-stage

[See other projects for this call](#)

Funding Scheme

[CP-FP - Small or medium-scale focused research project](#)

Coordinator



UPPSALA UNIVERSITET

EU contribution

€ 570 971,60

Total cost

No data

Address

VON KRAEMERS ALLE 4

751 05 Uppsala

 **Sweden** 

Region

Östra Sverige > Östra Mellansverige > Uppsala län

Activity type

Higher or Secondary Education Establishments

Links

[Contact the organisation](#)  [Website](#) 

[Participation in EU R&I programmes](#) 

[HORIZON collaboration network](#) 

Participants (9)



Immun System I.M.S. AB

 Sweden

EU contribution

€ 1 980 700,00

Address

Dag Hammerskjølds Vaeg 26
75183 UPPSALA 

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

- [Contact the organisation](#) 
- [Participation in EU R&I programmes](#) 
- [HORIZON collaboration network](#) 

Total cost

No data



MUKOVISZIDOSE INSTITUT - GEMEINNÜTZIGE GESELLSCHAFT FÜR FORSCHUNG UND THERAPIEENTWICKLUNG

 Germany

EU contribution

€ 1 305 000,00

Address

IN DEN DAUEN 6
53117 BONN 

Activity type

Research Organisations

Links

- [Contact the organisation](#) 
- [Website](#) 
- [Participation in EU R&I programmes](#) 
- [HORIZON collaboration network](#) 

Total cost

No data



REGION HOVEDSTADEN

 Denmark

EU contribution

€ 469 280,00

Address

KONGENS VAENGE 2

3400 Hillerod 

Region

Danmark > Hovedstaden > Københavns omegn

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

Links

[Contact the organisation](#)  [Website](#) 

[Participation in EU R&I programmes](#) 

[HORIZON collaboration network](#) 

Total cost

No data



VALSTYBINIS MOKSLINIŲ TYRIMŲ INSTITUTAS INOVATYVIOJOS MEDICINOS CENTRAS

 Lithuania

EU contribution

€ 90 000,00

Address

ZYGIMANTŲ 9

01102 Vilnius 

Region

Lietuva > Šaltinėlio regionas > Vilniaus apskritis

Activity type

Other

Links

[Contact the organisation](#) 

[Participation in EU R&I programmes](#) 

Total cost

No data



CYSTIC FIBROSIS EUROPE EV

 Germany

EU contribution

€ 113 520,36

Address

IN DEN DAUEN 6
53117 Bonn 

Region

Nordrhein-Westfalen > Köln > Bonn, Kreisfreie Stadt

Activity type

Other

Links

- [Contact the organisation](#) 
- [Participation in EU R&I programmes](#) 
- [HORIZON collaboration network](#) 

Total cost

No data



HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

 Germany

EU contribution

€ 625 900,00

Address

UNIVERSITAETSSTRASSE 1
40225 Dusseldorf 

Region

Nordrhein-Westfalen > Düsseldorf > Düsseldorf, Kreisfreie Stadt

Activity type

Higher or Secondary Education Establishments

Links

[Contact the organisation](#) [Website](#)
[Participation in EU R&I programmes](#)
[HORIZON collaboration network](#)

Total cost
No data



REGION STOCKHOLM

Sweden
EU contribution
€ 78 600,00

Address
HANTVERKARGATAN 45
104 22 Stockholm

Region
Östra Sverige > Stockholm > Stockholms län

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

Links
[Contact the organisation](#) [Website](#)
[Participation in EU R&I programmes](#)
[HORIZON collaboration network](#)

Total cost
No data



INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France
EU contribution
€ 19 408,04

Address
RUE DE TOLBIAC 101
75654 Paris

Region
Ile-de-France > Ile-de-France > Paris

Activity type

Research Organisations

Links

[Contact the organisation](#)  [Website](#) 

[Participation in EU R&I programmes](#) 

[HORIZON collaboration network](#) 

Total cost

No data



CONSORZIO ITALIANO PER LA RICERCA IN MEDICINA (C.I.R.M.)

 Italy

EU contribution

€ 122 800,00

Address

VIALE ORTLES 22/4

20139 MILANO MI 

Region

Nord-Ovest > Lombardia > Milano

Activity type

Research Organisations

Links

[Contact the organisation](#)  [Website](#) 

[Participation in EU R&I programmes](#) 

[HORIZON collaboration network](#) 

Total cost

No data

Last update: 29 May 2017

Permalink: <https://cordis.europa.eu/project/id/261095>

European Union, 2025